Epidemiology of Immune-Mediated Inflammatory Diseases: Incidence, Prevalence, Natural History, and Comorbidities

Abstract

Immune-mediated inflammatory diseases (IMID) present a group of common and highly disabling chronic conditions that share inflammatory pathways. Several incidence and prevalence studies of IMID during the past decades have reported a considerable variation of the disease occurrence among different populations. Overall, the estimated prevalence of IMID in Western society is 5%-7%. This article provides an overview of studies of the incidence, prevalence, natural history, and comorbidities of IMID.

Manifestaciones extraarticulares en pacientes con espondiloartritis. Características basales de la cohorte de pacientes con espondiloartritis del estudio AQUILES

“…Si bien la psoriasis y la uveítis pueden ser consideradas manifestaciones extraintestinales de las EsA, tanto estas como la EII pueden aparecer o evolucionar de forma independiente a la EsA y por ello este grupo de enfermedades con frecuencia se conoce como «enfermedades inflamatorias mediadas por inmunidad» (EIMI) [10][11][12] . Se ha observado que tanto factores gené-ticos como medioambientales desempeñan un papel decisivo en el desarrollo de estas afecciones 13,14 .…”

A Synthetic Mammalian Therapeutic Gene Circuit for Sensing and Suppressing Inflammation

“…To design an efficient therapeutic anti-inflammatory device, we aimed to combine the following characteristics: (1) real-time monitoring of physiologically relevant markers of inflammation; (2) an ability to switch to a therapeutically active (ON) state in response to physiologically relevant concentrations of an inflammatory marker; (3) efficient suppression of inflammation via sustained production of anti-inflammatory effectors triggered by the activation of the device; (4) control mechanism for preventing pre-mature inactivation of the device by the neutralization of inflammation markers by effectors in the immediate vicinity of the therapeutic cells; (5) and an ability to reset the device to the standby state by external signal (e.g., small-molecule inducer) that could potentially also be used in clinical applications applied by a physician.…”

“…4 The prevalence of inflammatory diseases associated with excessive and harmful inflammation is 5%-7%, even in societies with an advanced health care system. 5 Non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids are widely used and effective anti-inflammatory therapies, yet they can have adverse side effects. Currently, the most advanced clinically used therapies for inflammatory diseases are neutralizers of TNF-a (adalimumab, etanercept, and infliximab) and endogenous cytokine antagonists, such as anakinra (an IL-1b antagonist) that specifically and effectively inhibit the activity of pro-inflammatory cytokines.…”

Immune-Mediated Inflammatory Diseases and Other Comorbidities in Patients With Psoriasis: Baseline Characteristics of Patients in the AQUILES Study

“…Resultados: Se incluyeron 528 pacientes con psoriasis (edad media: 46,7 años; 60,2% hombres; 39,8% mujeres; 89,8% psoriasis en placas; mediana de PASI 3,2 [1,[5][6][7]4]). Presentaron otra EIMI 82 pacientes (15,5% [IC 95%: 12,(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)9]). El 14,0% (IC 95%: 11,3-17,2) presentó espondiloartritis (la mayoría de estos artritis psoriásica [prevalencia 13,1%, IC 95%: 10,5-16,2), el 1,3% EII (IC 95%: 0,6-2,7) y el 0,2% uveítis (IC 95%: 0,1-1,4).…”